Abbas M, Ploch E M, Wehling J, Schipper E, Janciauskiene S, Kreipe H H, Jonigk D
Institute of Pathology, Hannover medical School (MHH), Carl-Neuberg-Str. 1, 30625, Hannover, Germany,
Tumour Biol. 2014 Dec;35(12):12015-20. doi: 10.1007/s13277-014-2500-1. Epub 2014 Aug 24.
Routinely processed skin biopsies are still the mainstay for the diagnosis of melanocytic skin neoplasms (MSNs) and are considered the "gold standard" for individual patient management and clinical trials. The diagnostic challenge of melanocytic lesions of the skin prompts histopathologists to consider new diagnostic tools; among these, immunohistochemistry. We aimed to find putative new immunohistochemical markers, which can supplement the histological criteria used to detect dysplasia. In this immunohistochemical study, we chose a panel of promising biomarkers which could potentially differentiate between different MSN entities. These included α-methylacyl-coenzyme A racemase (AMACR; p504s), which is involved in the degradation of branched chained fatty acid derivates. We analysed a cohort of benign nevi and malignant melanomas. The design of the study included 78 melanocytic skin neoplasms (26 malignant melanomas and 52 benign nevi) in a tissue microarray. Immunohistochemistry of cyclin-dependent kinase inhibitor 2A (p16Ink4a), methylacyl-coenzyme A racemase (AMACR), cyclin D1, and E-cadherin was performed and assessed. We have observed that the p16Ink4a, AMACR, cyclin D1, and E-cadherin showed no exclusive staining for nevi or melanomas. However, a significant overexpression of AMACR was found in malignant melanomas compared to benign nevi. AMACR overexpression was also associated with an increased p16Ink4a staining. Our results suggest AMACR as an immunohistochemical marker for distinguishing malignant melanomas and dysplastic nevi from conventional melanocytic nevi.
常规处理的皮肤活检仍是诊断黑素细胞性皮肤肿瘤（MSN）的主要方法，被视为个体患者管理和临床试验的“金标准”。皮肤黑素细胞病变的诊断挑战促使组织病理学家考虑新的诊断工具，其中包括免疫组织化学。我们旨在寻找可能的新免疫组织化学标志物，以补充用于检测发育异常的组织学标准。在这项免疫组织化学研究中，我们选择了一组有前景的生物标志物，它们可能有助于区分不同的MSN实体。这些标志物包括α-甲基酰基辅酶A消旋酶（AMACR；p504s），它参与支链脂肪酸衍生物的降解。我们分析了一组良性痣和恶性黑色素瘤。研究设计包括在组织芯片中纳入78例黑素细胞性皮肤肿瘤（26例恶性黑色素瘤和52例良性痣）。对细胞周期蛋白依赖性激酶抑制剂2A（p16Ink4a）、甲基酰基辅酶A消旋酶（AMACR）、细胞周期蛋白D1和E-钙黏蛋白进行免疫组织化学检测并评估。我们观察到，p16Ink4a、AMACR、细胞周期蛋白D1和E-钙黏蛋白对痣或黑色素瘤均无特异性染色。然而，与良性痣相比，恶性黑色素瘤中AMACR有明显的过表达。AMACR过表达还与p16Ink4a染色增加有关。我们的结果表明，AMACR可作为一种免疫组织化学标志物，用于区分恶性黑色素瘤和发育异常痣与传统黑素细胞痣。
